{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:00:12Z","timestamp":1793692812078,"version":"4.5.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jacc.2021.07.048","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T15:02:40Z","timestamp":1632150160000},"page":"1372-1384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Intracranial Hemorrhage During Dual Antiplatelet Therapy"],"prefix":"10.1016","volume":"78","author":[{"given":"Andrew C.T.","family":"Ha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Rutka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Claiborne","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. David","family":"Mazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.07.048_bib1","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.07.048_bib2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.07.048_bib3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.07.048_bib4","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.048_bib5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.048_bib6","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","article-title":"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial","volume":"394","author":"Bhatt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.07.048_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.048_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005795","article-title":"Impact of clopidogrel therapy on mortality and cancer in patients with cardiovascular and cerebrovascular disease: a patient-level meta-analysis","volume":"11","author":"Elmariah","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2021.07.048_bib9","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(18)31878-6","article-title":"Intracerebral haemorrhage: current approaches to acute management","volume":"392","author":"Cordonnier","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.07.048_bib10","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/01.STR.0000170642.39876.f2","article-title":"Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas","volume":"36","author":"Hart","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2021.07.048_bib11","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.07.048_bib12","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.07.048_bib13","first-page":"2429","article-title":"GBD 2016 Lifetime Risk of Stroke Collaborators. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016","volume":"379","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.048_bib14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.07.048_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202575","article-title":"Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: nationwide pharmacoepidemiological study","volume":"13","author":"Gulati","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2021.07.048_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/ene.13193","article-title":"Does prior antiplatelet therapy influence hematoma volume and hematoma growth following intracerebral hemorrhage? Results from a prospective study and a meta-analysis","volume":"24","author":"Camps-Renom","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jacc.2021.07.048_bib17","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/STROKEAHA.117.016290","article-title":"Association between previous use of antiplatelet therapy and intracerebral hemorrhage outcomes","volume":"48","author":"Khan","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2021.07.048_bib18","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/S2468-2667(16)30017-2","article-title":"Epidemiology of traumatic brain injuries in Europe: a cross-sectional analysis","volume":"1","author":"Majdan","year":"2016","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.jacc.2021.07.048_bib19","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1474-4422(19)30232-7","article-title":"Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study","volume":"18","author":"Steyerberg","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2021.07.048_bib20","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1093\/eurheartj\/ehz707","article-title":"THEMIS and THEMIS-PCI","volume":"40","author":"Bhatt","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.07.048_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/neu.2015.4393","article-title":"Systematic review and meta-analysis: is pre-injury antiplatelet therapy associated with traumatic intracranial hemorrhage?","volume":"34","author":"van den Brand","year":"2017","journal-title":"J\u00a0Neurotrauma"},{"key":"10.1016\/j.jacc.2021.07.048_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2019.02.080","article-title":"Antithrombotics: from aspirin to DOACs in coronary artery disease and atrial fibrillation","volume":"74","author":"Verheugt","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.07.048_bib23","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2019.03.501","article-title":"Aspirin for primary prevention of cardiovascular events","volume":"73","author":"Abdelaziz","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.07.048_bib24","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y 12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.07.048_bib26","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.048_bib27","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.048_bib28","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.048_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.048_bib30","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.117.032180","article-title":"Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization","volume":"137","author":"Savonitto","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.07.048_bib31","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.jacc.2019.03.011","article-title":"Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis: TREAT trial","volume":"73","author":"Berwanger","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.07.048_bib32","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","article-title":"Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial","volume":"140","author":"Park","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.07.048_bib33","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.048_bib34","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial","volume":"395","author":"Gimbel","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.07.048_bib35","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaneurol.2019.1120","article-title":"Frequency of intracranial hemorrhage with low-dose aspirin in individuals without symptomatic cardiovascular disease: a systematic review and meta-analysis","volume":"76","author":"Huang","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacc.2021.07.048_bib36","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/CIRCULATIONAHA.112.141572","article-title":"A\u00a0history of stroke\/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease","volume":"127","author":"Ducrocq","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.07.048_bib37","article-title":"Ischemic and bleeding risk after percutaneous coronary intervention in patients with prior ischemic and hemorrhagic stroke","volume":"8","author":"Natsuaki","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.07.048_bib38","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1212\/WNL.0000000000004289","article-title":"Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets: S2TOP-BLEED","volume":"89","author":"Hilkens","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2021.07.048_bib39","unstructured":"US Food and Drug Administration. Highlights of prescribing information. Efficient (prasugrel). Accessed June 18, 2021. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022307s002lbl.pdf"},{"key":"10.1016\/j.jacc.2021.07.048_bib40","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/STROKEAHA.117.019259","article-title":"External validation of risk scores for major bleeding in a population-based cohort of transient ischemic attack and ischemic stroke patients","volume":"49","author":"Hilkens","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2021.07.048_bib41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/jnnp.2004.059923","article-title":"Cerebrovascular Cohort Studies Collaboration (CCSC). Predictors of risk of intracerebral haemorrhage in patients with a history of TIA or minor ischaemic stroke","volume":"77","author":"Ariesen","year":"2006","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jacc.2021.07.048_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000453459","article-title":"The Intracranial-B2LEED3S score and the risk of intracranial hemorrhage in ischemic stroke patients under antiplatelet treatment","volume":"43","author":"Amarenco","year":"2017","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jacc.2021.07.048_bib43","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1161\/CIRCULATIONAHA.121.053782","article-title":"Efficacy and safety of using dual versus monotherapy antiplatelet agents in secondary stroke prevention: systematic review and meta-analysis of randomized controlled clinical trials","volume":"143","author":"Trifan","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.07.048_bib44","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug eluting stents: risk scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.07.048_bib45","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.07.048_bib46","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.07.048_bib47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijcard.2017.10.103","article-title":"Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: the BleeMACS score","volume":"254","author":"Raposeiras-Roub\u00edn","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2021.07.048_bib48","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for high bleeding risk","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.07.048_bib49","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial","volume":"387","author":"Baharoglu","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.07.048_bib50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M14-1589","article-title":"Platelet transfusion: a clinical practice guideline from the AABB","volume":"162","author":"Kaufman","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2021.07.048_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1538-7836.2006.02245.x","article-title":"Normalization\u00a0of platelet reactivity in clopidogrel-treated subjects","volume":"5","author":"Vilahur","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2021.07.048_bib52","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/jth.12058","article-title":"Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation","volume":"11","author":"Zafar","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2021.07.048_bib53","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.002786","article-title":"Efficacy of ex\u00a0vivo autologous and in\u00a0vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study","volume":"8","author":"O\u2019Connor","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2021.07.048_bib54","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s00392-017-1128-8","article-title":"Reversal of the platelet inhibitory effect of the P2Y 12 inhibitors clopidogrel, prasugrel, and ticagrelor in\u00a0vitro: a new approach to an old issue","volume":"106","author":"Schoener","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacc.2021.07.048_bib55","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.acvd.2018.10.004","article-title":"Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications","volume":"112","author":"Godier","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2021.07.048_bib56","first-page":"135","article-title":"Ticagrelor Removal From Human Blood","volume":"2","author":"Angheloiu","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jacc.2021.07.048_bib57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.athoracsur.2018.12.032","article-title":"Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding","volume":"108","author":"Hassan","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2021.07.048_bib58","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/jclinpath-2016-204117","article-title":"Ticagrelor reversal: in\u00a0vitro assessment of four haemostatic agents","volume":"70","author":"Calmette","year":"2017","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jacc.2021.07.048_bib59","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jcpt.12130","article-title":"The effect of\u00a0desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor","volume":"39","author":"Teng","year":"2014","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jacc.2021.07.048_bib60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13181-012-0275-6","article-title":"Reversal of thienopyridine-induced platelet dysfunction following desmopressin administration","volume":"9","author":"Levine","year":"2013","journal-title":"J\u00a0Med Toxicol"},{"issue":"19","key":"10.1016\/j.jacc.2021.07.048_bib61","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa1901778","article-title":"Antibody-based ticagrelor reversal agent in healthy volunteers","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.048_bib62","unstructured":"US Food and Drug Administration. Breakthrough Therapy Designation Requests. Accessed June 18, 2021. www.fda.gov\/drugs\/ind-activity\/breakthrough-therapy-designation-requests"},{"key":"10.1016\/j.jacc.2021.07.048_bib63","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/S0140-6736(19)30840-2","article-title":"RESTART Collaboration: effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomized, open-label trial","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.07.048_bib64","unstructured":"Centers for Disease Control and Prevention. Prevention of Traumatic Brain Injury. Accessed June 18, 2021. www.cdc.gov\/traumaticbraininjury\/prevention.html"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721057867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721057867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:45:56Z","timestamp":1760017556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721057867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":63,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0735109721057867"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.07.048","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracranial Hemorrhage During Dual Antiplatelet Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.07.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}